Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- PRM-151 Seen to Slow Decline in Lung Function of IPF Patients in Phase 2 Trial
- New Lung-on-a-chip Technology Captures Fibrosis Progression and May Speed Treatment Discovery, Study Reports
- #ATS2018 — Prometic’s PBI-4050, Ryplazim Have Potential to Prevent Lung Fibrosis, Latest Data Show
- #ATS2018 – Ofev May Reduce Risk of Death in IPF, Has Safe Profile, Trials Show
- #ATS2018 – Results of SM04646 Mouse Study for IPF is on ATS Agenda
- Esbriet and Ofev Use Prior to Lung Transplant Seen as Safe for IPF Patients in Study
- Ofev Preserves Pulmonary Function of IPF Patients Awaiting a Lung Transplant, Study Finds
IPF News:
- Breathing Easier on the Canadian West Coast
- PF Brain Fog Struggles and Solutions
- Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests
- Yankees’ Bernie Williams Talks About His Father’s Journey With IPF
- 4 Common Coughing Triggers for Idiopathic Pulmonary Fibrosis
- Top 5 Recommended Reads for Pulmonary Fibrosis
- 3 Useful Resources for IPF Caregivers
Esbriet News:
- PRM-151 Seen to Slow Decline in Lung Function of IPF Patients in Phase 2 Trial
- France Foundation-Genentech Initiative to Improve IPF Diagnosis, Treatment at Local Level
- New Lung-on-a-chip Technology Captures Fibrosis Progression and May Speed Treatment Discovery, Study Reports
- #ATS2018 – Esbriet Lowers Risk of Seasonal IPF Flares Leading to Hospitalizations, Phase 3 Data Show
- #ATS2018 – Results of SM04646 Mouse Study for IPF is on ATS Agenda
- Esbriet and Ofev Use Prior to Lung Transplant Seen as Safe for IPF Patients in Study
- ‘Support and Respect’ Shown by Nurses Helpful and Comforting, Says IPF Patient as Thank You
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
- IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds
- Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
FDA News:
- US ‘Right to Try’ Law Meets with Mix of Praise and Criticism, Including Among Those with Rare Diseases
- Reviva’s Investigational Therapy RP5063 Receives FDA Orphan Drug Status for IPF Treatment
- Rare Disease Groups Welcome FDA’s Embrace of ‘Real World’ Data in Clinical Trials
- US Lawmakers Urge Bipartisan Support for Rare Disease Research, Patients’ Needs
- Rare Disease Groups, Patients Differ on ‘Right to Try’ Bill Before US Congress
- FDA Grants Orphan Drug Status to Prometic’s Pulmonary Fibrosis Therapy Ryplazim
- Rare Disease Patient Groups Unite to Preserve Orphan Drug Tax Credit in US